Literature DB >> 22748650

Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid).

David W Roberts1, Pablo A Valdés, Brent T Harris, Alexander Hartov, Xiaoyao Fan, Songbai Ji, Frederic Leblond, Tor D Tosteson, Brian C Wilson, Keith D Paulsen.   

Abstract

5-Aminolevulinic acid (5-ALA)-induced tumor fluorescence can be used to identify tissue for resection using an adapted operating microscope. A multi-institutional clinical trial comparing fluorescence-guided versus white light tumor resection reported significant improvement in completeness of resection and 6-month progression-free survival. The degree of 5-ALA-induced fluorescence correlates with histopathologic grade of tumor, degree of tumor cell infiltration, and proliferation indices. Quantitative methodologies for assessment of tissue fluorescence have significantly improved the ability to detect tumor tissue and intraoperative diagnostic performance. These developments extend the applicability of this technology to additional tumor histologies and provide the rationale for further instrumentation development.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748650      PMCID: PMC3761370          DOI: 10.1016/j.nec.2012.04.001

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  8 in total

1.  Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article.

Authors:  David W Roberts; Pablo A Valdés; Brent T Harris; Kathryn M Fontaine; Alexander Hartov; Xiaoyao Fan; Songbai Ji; S Scott Lollis; Brian W Pogue; Frederic Leblond; Tor D Tosteson; Brian C Wilson; Keith D Paulsen
Journal:  J Neurosurg       Date:  2010-04-09       Impact factor: 5.115

2.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

3.  Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article.

Authors:  Walter Stummer; Jörg-Christian Tonn; Hubertus Maximilian Mehdorn; Ulf Nestler; Kea Franz; Claudia Goetz; Andrea Bink; Uwe Pichlmeier
Journal:  J Neurosurg       Date:  2010-04-16       Impact factor: 5.115

4.  δ-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy.

Authors:  Pablo A Valdés; Anthony Kim; Marco Brantsch; Carolyn Niu; Ziev B Moses; Tor D Tosteson; Brian C Wilson; Keith D Paulsen; David W Roberts; Brent T Harris
Journal:  Neuro Oncol       Date:  2011-08       Impact factor: 12.300

5.  Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients.

Authors:  W Stummer; A Novotny; H Stepp; C Goetz; K Bise; H J Reulen
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

6.  Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker.

Authors:  Pablo A Valdés; Frederic Leblond; Anthony Kim; Brent T Harris; Brian C Wilson; Xiaoyao Fan; Tor D Tosteson; Alex Hartov; Songbai Ji; Kadir Erkmen; Nathan E Simmons; Keith D Paulsen; David W Roberts
Journal:  J Neurosurg       Date:  2011-03-25       Impact factor: 5.115

7.  Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.

Authors:  Uwe Pichlmeier; Andrea Bink; Gabriele Schackert; Walter Stummer
Journal:  Neuro Oncol       Date:  2008-07-30       Impact factor: 12.300

8.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

  8 in total
  23 in total

1.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Authors:  Eben L Rosenthal; Jason M Warram; Esther de Boer; Thomas K Chung; Melissa L Korb; Margie Brandwein-Gensler; Theresa V Strong; Cecelia E Schmalbach; Anthony B Morlandt; Garima Agarwal; Yolanda E Hartman; William R Carroll; Joshua S Richman; Lisa K Clemons; Lisle M Nabell; Kurt R Zinn
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

Review 2.  Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review.

Authors:  Sonya E L Craig; James Wright; Andrew E Sloan; Susann M Brady-Kalnay
Journal:  World Neurosurg       Date:  2016-02-23       Impact factor: 2.104

3.  Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection.

Authors:  Willemieke S Tummers; Jason M Warram; Kiranya E Tipirneni; John Fengler; Paula Jacobs; Lalitha Shankar; Lori Henderson; Betsy Ballard; T Joshua Pfefer; Brian W Pogue; Jamey P Weichert; Michael Bouvet; Jonathan Sorger; Christopher H Contag; John V Frangioni; Michael F Tweedle; James P Basilion; Sanjiv S Gambhir; Eben L Rosenthal
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

4.  Near infrared fluorescence for image-guided surgery.

Authors:  Summer L Gibbs
Journal:  Quant Imaging Med Surg       Date:  2012-09

5.  Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.

Authors:  Giuseppe Carlucci; Brandon Carney; Christian Brand; Susanne Kossatz; Christopher P Irwin; Sean D Carlin; Edmund J Keliher; Wolfgang Weber; Thomas Reiner
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

6.  Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgery.

Authors:  Pablo A Valdés; Valerie Jacobs; Brent T Harris; Brian C Wilson; Frederic Leblond; Keith D Paulsen; David W Roberts
Journal:  J Neurosurg       Date:  2015-07-03       Impact factor: 5.115

7.  5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo.

Authors:  Pablo A Valdes; Kimon Bekelis; Brent T Harris; Brian C Wilson; Frederic Leblond; Anthony Kim; Nathan E Simmons; Kadir Erkmen; Keith D Paulsen; David W Roberts
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

8.  Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use.

Authors:  Kimberley S Samkoe; Jason R Gunn; Kayla Marra; Sally M Hull; Karen L Moodie; Joachim Feldwisch; Theresa V Strong; Daniel R Draney; P Jack Hoopes; David W Roberts; Keith Paulsen; Brian W Pogue
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

9.  The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors.

Authors:  M Preuß; C Renner; W Krupp; H Christiansen; L Fischer; A Merkenschlager; W Kieß; W Müller; N Manzo; J Meixensberger; U Nestler
Journal:  Childs Nerv Syst       Date:  2013-05-25       Impact factor: 1.475

10.  The use of 5-aminolevulinic acid in resection of pediatric brain tumors: a critical review.

Authors:  Chenran Zhang; Frederick A Boop; John Ruge
Journal:  J Neurooncol       Date:  2018-11-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.